Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.67 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.67 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620186 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL621573 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2436966 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL620187 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL621574 | 1.00 | CHRNB2 (0.67) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Iodide SCHEMBL3455134 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Iodide SCHEMBL3455248 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Iodide SCHEMBL3455130 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Iodide SCHEMBL3455132 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Iodide SCHEMBL3455251 | 0.98 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4240815-B2 | — | — | 2009-03-18 | — | — | JP | claimed |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-06-12 | — | — | US | claimed |
| EP-1814853-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | Targacept, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| US-20060264445-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-11-23 | — | — | US | claimed |
| US-7060826-B2 | Compounds capable of activating cholinergic receptors | TARGAEEPT, INC. (US) | 2006-06-13 | — | — | US | claimed |
| WO-2006053039-A2 | HYDROXYBENZOATE SALTS OF METANICOTINE COMPOUNDS | TARGACEPT, INC. (US) | 2006-05-18 | — | — | WO | claimed |
| JP-2006511482-A | — | — | 2006-04-06 | — | — | JP | claimed |
| US-20050282846-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAN S | 2005-12-22 | — | — | US | claimed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | claimed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | claimed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | claimed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | claimed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | claimed |
| JP-2002518373-A | — | — | 2002-06-25 | — | — | JP | claimed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | claimed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | claimed |
| EP-1086082-A1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2001-03-28 | — | — | EP | claimed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | claimed |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA (US) | 2018-04-05 | — | — | US | disclosed |
| US-9782404-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2017-10-10 | — | — | US | disclosed |
| US-9463190-B2 | Methods of treating disease-induced ataxia and non-ataxic imbalance | UNIVERSITY OF SOUTH FLORIDA (US) | 2016-10-11 | — | — | US | disclosed |
| US-20140371208-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA | 2014-12-18 | — | — | US | disclosed |
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288420-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | UNIVERSITY OF SOUTH FLORIDA | 2011-09-29 | — | — | US | disclosed |
| US-20110059905-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | UNIVERSITY OF SOUTH FLORIDA | 2011-03-10 | — | — | US | disclosed |
| EP-2253616-A1 | Process for the preparation of compounds capable of activating cholinergic receptors | Targacept, Inc. (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7790757-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790757-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-09-04 | — | — | US | disclosed |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-09-04 | — | — | US | disclosed |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-06-12 | — | — | US | disclosed |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM SCOTT | 2008-06-12 | — | — | US | disclosed |
| US-7307092-B2 | Compounds Capable of Activating Cholinergic Receptors | TARGACEPT, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307092-B2 | Compounds Capable of Activating Cholinergic Receptors | TARGACEPT, INC. (US) | 2007-12-11 | — | — | US | disclosed |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-12-28 | — | — | US | disclosed |
| US-20060264445-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-11-23 | — | — | US | disclosed |
| US-20060264445-A1 | Compounds Capable of Activating Cholinergic Receptors | CALDWELL WILLIAM S | 2006-11-23 | — | — | US | disclosed |
| US-7060826-B2 | Compounds capable of activating cholinergic receptors | TARGAEEPT, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-7060826-B2 | Compounds capable of activating cholinergic receptors | TARGAEEPT, INC. (US) | 2006-06-13 | — | — | US | disclosed |
| US-7045538-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-6979695-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-12-27 | — | — | US | disclosed |
| US-20050282846-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAN S | 2005-12-22 | — | — | US | disclosed |
| US-20050282846-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAN S | 2005-12-22 | — | — | US | disclosed |
| US-6958399-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| US-6958399-B2 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. (US) | 2005-10-25 | — | — | US | disclosed |
| EP-1556352-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | Targacept, Inc. (US) | 2005-07-27 | — | — | EP | disclosed |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-07-07 | — | — | US | disclosed |
| EP-1550445-A1 | Method for the treatment of female specific pain using metanicotine derivatives | Wake Forest University (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-06-16 | — | — | US | disclosed |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM S (US) | 2005-06-16 | — | — | US | disclosed |
| EP-1056458-B1 | TREATMENT OF CHRONIC PAIN | UNIV WAKE FOREST (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | disclosed |
| EP-1086082-B9 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | disclosed |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CALDWELL WILLIAM SCOTT (US) | 2004-10-28 | — | — | US | disclosed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | disclosed |
| EP-1086082-B1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | TARGACEPT INC (US) | 2004-08-18 | — | — | EP | disclosed |
| WO-2004031151-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | TARGACEPT, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | TARGACEPT, INC. | 2003-07-03 | — | — | US | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | TARGACEPT, INC. | 2002-05-02 | — | — | US | disclosed |
| EP-1056458-A4 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | UNIV WAKE FOREST (US) | 2001-06-20 | — | — | EP | disclosed |
| US-6248744-B1 | ADMINISTERING AN ANALGESIC DOSAGE OF AN AMINOALKENYL(PYRIDINE OR PYRIMIDINE) DERIVATIVE TO RELIEVE PAIN OF MENSTRUATION, OVULATION, PREGNANCY, CHILDBIRTH, CANCER, BONE DISORDERS, OR INJURIES | WAKE FOREST UNIVERSITY | 2001-06-19 | — | — | US | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
| US-6232316-B1 | SUCH AS PARKINSON'S DISEASE, TOURETTE'S SYNDROME, SCHIZOPHRENIA, AND SENILE DEMENTIA OF ALZHEIMERS DISEASE | TARGACEPT, INC. | 2001-05-15 | — | — | US | disclosed |
| EP-1086082-A1 | ARYLSUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 2001-03-28 | — | — | EP | disclosed |
| EP-1056458-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | Wake Forest University (US) | 2000-12-06 | — | — | EP | disclosed |
| WO-1999065876-A1 | ARYL SUBSTITUTED OLEFINIC AMINES AND THEIR USE AS CHOLINERGIC RECEPTORS AGONISTS | R.J. REYNOLDS TOBACCO COMPANY (US) | 1999-12-23 | — | — | WO | disclosed |
| WO-1999043322-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | WAKE FOREST UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| WO-1999043322-A1 | METHOD FOR THE TREATMENT OF PAIN, INCLUDING CHRONIC AND FEMALE SPECIFIC PAIN | WAKE FOREST UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052497-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20100222395-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20050131034-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20140371208-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB2 9/4885CHRNA4 7/4885CHRNB4 10/4885 |
| US-20050148611-A1 | Compounds capable of activating cholinergic receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885CHRNB4 13/4885 |
| US-20100204481-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20030125345-A1 | Nicotinic compounds; treating central nervous system disorders | SLC6A2, CHRNA6, CHRNA10 | CHRNB2 9/4885CHRNA4 7/4885CHRNB4 14/4885 |
| US-20080139809-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20110059905-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB2 9/4885CHRNA4 7/4885CHRNB4 10/4885 |
| US-20080214628-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20180092916-A1 | METHODS OF TREATING DISEASE-INDUCED ATAXIA AND NON-ATAXIC IMBALANCE | CHRNA6, CHRNA7, CHRNA2 | CHRNB2 9/4885CHRNA4 7/4885CHRNB4 10/4885 |
| US-20060264445-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20040214835-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20110237597-A1 | METHOD OF TREATING PERIPHERAL NERVE SENSORY LOSS USING COMPOUNDS HAVING NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ACHE, CHRNA6, CHRNB2 | CHRNB2 3/4885CHRNA4 9/4885CHRNB4 7/4885 |
| US-20050282846-A1 | Compounds capable of activating cholinergic receptors | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
| US-20100121061-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885CHRNB4 13/4885 |
| US-20060293289-A1 | Compounds Capable of Activating Cholinergic Receptors | CHRM3, CHRM5, CHRM4 | CHRNB2 14/4885CHRNA4 9/4885CHRNB4 13/4885 |
| US-20100160390-A1 | COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS | CHRNA4, CHRNB4, CHRM4 | CHRNB2 4/4885CHRNA4 1/4885CHRNB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.